ERBB2 and non-small cell lung carcinoma: Human epidermal growth factor 2 (<i>HER2</i>) mutations are uncommon in non-small cell lung cancer (NSCLC), and the lack of established, effective, targeted drugs has resulted in a persistently poor prognosis.